Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

Galan, 2021 RBR-8h7q82

ivermectin (n=53) vs. chloroquine (n=115)

randomized controlled trial   some concerns about risk of bias

Studied treatment

Ivermectin
14 mg once at day 0 1 placebo tablet at day 0, and once daily from day 1 to day 2, 1 placebo tablet daily from day 3 to 4, total dose 42 mg

Control treatment

Hydroxychloroquine or Chloroquine
HCQ : 400 mg twice on day 0, and once daily from day 1 to day 4, total dose 2.4 gCQ : 450 mg, twice on day 0, and once daily from day 1 to day 4, total dose 2.7 g

3 arms: chloroquine, hydroxychloroquine, ivermectin.

Patients

COVID-19 severe or critically

Method

Double-blind.

Single center, Brasil.

Phase II.

Remark

Okumuş, 2020 NCT04646109

ivermectin (n=30) vs. standard of care (n=30)

randomized controlled trial   high risk of bias

Studied treatment

ivermectin soc
Ivermectin (Enteral solution at 200 microgr/kg/day (9mg between 36-50 kg, 12mg between 51-65 kg, 15mg between 66-79 kg and 200 microgram/kg in > 80 kg) for 5 days

Control treatment

Soc
Favipiravir (2x1600mg loading dose followed by 2x600mg maintenance dose, po, total 5 days); Hydroxychloroquine (2x400mg loading dose followed by 2x200mg, po, 5 days);Azithromycin (500mg first day loading dose, followed by 250mg/day, po, total 5 days)

Patients

COVID-19 severe or critically

Method

single blind

4 centres, Turkey

described as crossover assignment and several inconsistencies in the description of endpoints in clinicalTrials.gov

Remark

results up-dated with pre-print